These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 32234363)

  • 1. Acquisition of Cabozantinib-Sensitive MET D1228N Mutation During Progression on Crizotinib in MET-Amplified Triple-Negative Breast Cancer.
    Parsons BM; Meier DR; Richmond CS; Gurda GT; Lofgren KA; Burkard ME; Deming DA; Kenny PA
    Clin Breast Cancer; 2020 Aug; 20(4):e433-e438. PubMed ID: 32234363
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Circulating tumor DNA profiling by next generation sequencing reveals heterogeneity of crizotinib resistance mechanisms in a gastric cancer patient with MET amplification.
    Du J; Wu X; Tong X; Wang X; Wei J; Yang Y; Chang Z; Mao Y; Shao YW; Liu B
    Oncotarget; 2017 Apr; 8(16):26281-26287. PubMed ID: 28460431
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acquired MET D1228N Mutations Mediate Crizotinib Resistance in Lung Adenocarcinoma with ROS1 Fusion: A Case Report.
    Wang Y; Chen Z; Han X; Li J; Guo H; Shi J
    Oncologist; 2021 Mar; 26(3):178-181. PubMed ID: 33000474
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overcoming MET-Dependent Resistance to Selective RET Inhibition in Patients with RET Fusion-Positive Lung Cancer by Combining Selpercatinib with Crizotinib.
    Rosen EY; Johnson ML; Clifford SE; Somwar R; Kherani JF; Son J; Bertram AA; Davare MA; Gladstone E; Ivanova EV; Henry DN; Kelley EM; Lin M; Milan MSD; Nair BC; Olek EA; Scanlon JE; Vojnic M; Ebata K; Hechtman JF; Li BT; Sholl LM; Taylor BS; Ladanyi M; Jänne PA; Rothenberg SM; Drilon A; Oxnard GR
    Clin Cancer Res; 2021 Jan; 27(1):34-42. PubMed ID: 33082208
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overcoming Acquired Resistance Mutation MET D1228N to Crizotinib With Cabozantinib in NSCLC With MET Exon 14 Skipping Mutation.
    Pruis MA; Paats MS; Geurts WRR; Dubbink HJ; Dingemans AC
    JCO Precis Oncol; 2021 Nov; 5():849-853. PubMed ID: 34994615
    [No Abstract]   [Full Text] [Related]  

  • 6. Spectrum of Mechanisms of Resistance to Crizotinib and Lorlatinib in
    Lin JJ; Choudhury NJ; Yoda S; Zhu VW; Johnson TW; Sakhtemani R; Dagogo-Jack I; Digumarthy SR; Lee C; Do A; Peterson J; Prutisto-Chang K; Malik W; Hubbeling HG; Langenbucher A; Schoenfeld AJ; Falcon CJ; Temel JS; Sequist LV; Yeap BY; Lennerz JK; Shaw AT; Lawrence MS; Ou SI; Hata AN; Drilon A; Gainor JF
    Clin Cancer Res; 2021 May; 27(10):2899-2909. PubMed ID: 33685866
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ability of the Met kinase inhibitor crizotinib and new generation EGFR inhibitors to overcome resistance to EGFR inhibitors.
    Nanjo S; Yamada T; Nishihara H; Takeuchi S; Sano T; Nakagawa T; Ishikawa D; Zhao L; Ebi H; Yasumoto K; Matsumoto K; Yano S
    PLoS One; 2013; 8(12):e84700. PubMed ID: 24386407
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MET Alterations Are a Recurring and Actionable Resistance Mechanism in ALK-Positive Lung Cancer.
    Dagogo-Jack I; Yoda S; Lennerz JK; Langenbucher A; Lin JJ; Rooney MM; Prutisto-Chang K; Oh A; Adams NA; Yeap BY; Chin E; Do A; Marble HD; Stevens SE; Digumarthy SR; Saxena A; Nagy RJ; Benes CH; Azzoli CG; Lawrence MS; Gainor JF; Shaw AT; Hata AN
    Clin Cancer Res; 2020 Jun; 26(11):2535-2545. PubMed ID: 32086345
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acquired Resistance to Crizotinib in NSCLC with MET Exon 14 Skipping.
    Heist RS; Sequist LV; Borger D; Gainor JF; Arellano RS; Le LP; Dias-Santagata D; Clark JW; Engelman JA; Shaw AT; Iafrate AJ
    J Thorac Oncol; 2016 Aug; 11(8):1242-1245. PubMed ID: 27343442
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Responses to crizotinib and cabozantinib in patient with lung adenocarcinoma harboring mesenchymal-epithelial transition factor exon 14 skipping mutation: A case report.
    Qin RY; Liu LS; Zhang HY; Lu CH; Guo XY; Zhang LY; Yuan XB; Xue HH
    Medicine (Baltimore); 2021 Jan; 100(4):e24300. PubMed ID: 33530219
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acquired Mechanism of Crizotinib Resistance in NSCLC with MET Exon 14 Skipping.
    Jin W; Shan B; Liu H; Zhou S; Li W; Pan J; Lin L; Hu D; Pan Y
    J Thorac Oncol; 2019 Jul; 14(7):e137-e139. PubMed ID: 31055074
    [No Abstract]   [Full Text] [Related]  

  • 12. Crizotinib treatment for patients with EGFR mutation positive NSCLC that acquire cMET amplification after EGFR TKI therapy results in short-lived and heterogeneous responses.
    van Veggel B; de Langen AJ; Hashemi S; Monkhorst K; Rosenberg EH; Heideman DAM; Radonic T; Smit EF
    Lung Cancer; 2018 Oct; 124():130-134. PubMed ID: 30268451
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined effect of cabozantinib and gefitinib in crizotinib-resistant lung tumors harboring ROS1 fusions.
    Kato Y; Ninomiya K; Ohashi K; Tomida S; Makimoto G; Watanabe H; Kudo K; Matsumoto S; Umemura S; Goto K; Ichihara E; Ninomiya T; Kubo T; Sato A; Hotta K; Tabata M; Toyooka S; Maeda Y; Kiura K
    Cancer Sci; 2018 Oct; 109(10):3149-3158. PubMed ID: 30053332
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Amplification of Wild-type
    Bahcall M; Awad MM; Sholl LM; Wilson FH; Xu M; Wang S; Palakurthi S; Choi J; Ivanova EV; Leonardi GC; Ulrich BC; Paweletz CP; Kirschmeier PT; Watanabe M; Baba H; Nishino M; Nagy RJ; Lanman RB; Capelletti M; Chambers ES; Redig AJ; VanderLaan PA; Costa DB; Imamura Y; Jänne PA
    Clin Cancer Res; 2018 Dec; 24(23):5963-5976. PubMed ID: 30072474
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Combined Therapy of Cabozantinib, Crizotinib, and Osimertinib in a Lung Cancer Patient with Acquired MET Amplification and Resistance Mutations.
    Jóri B; Vössing C; Pirngruber J; Willing EM; Arndt K; Falk M; Tiemann M; Heukamp LC; Hoffknecht P
    Curr Oncol; 2023 Sep; 30(10):8805-8814. PubMed ID: 37887535
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Crizotinib-resistant
    Shen B; Wu F; Ye J; Liang R; Wang R; Yu R; Wu X; Shao YW; Feng J
    Future Oncol; 2019 Aug; 15(22):2585-2593. PubMed ID: 31339066
    [No Abstract]   [Full Text] [Related]  

  • 17. Response and acquired resistance to crizotinib in Chinese patients with lung adenocarcinomas harboring MET Exon 14 splicing alternations.
    Dong HJ; Li P; Wu CL; Zhou XY; Lu HJ; Zhou T
    Lung Cancer; 2016 Dec; 102():118-121. PubMed ID: 27987579
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II and Biomarker Study of Cabozantinib in Metastatic Triple-Negative Breast Cancer Patients.
    Tolaney SM; Ziehr DR; Guo H; Ng MR; Barry WT; Higgins MJ; Isakoff SJ; Brock JE; Ivanova EV; Paweletz CP; Demeo MK; Ramaiya NH; Overmoyer BA; Jain RK; Winer EP; Duda DG
    Oncologist; 2017 Jan; 22(1):25-32. PubMed ID: 27789775
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Crizotinib with or without an EGFR-TKI in treating EGFR-mutant NSCLC patients with acquired MET amplification after failure of EGFR-TKI therapy: a multicenter retrospective study.
    Wang W; Wang H; Lu P; Yu Z; Xu C; Zhuang W; Song Z
    J Transl Med; 2019 Feb; 17(1):52. PubMed ID: 30791921
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Case report: HER2 amplification as a resistance mechanism to crizotinib in NSCLC with MET exon 14 skipping.
    Ding G; Wang J; Ding P; Wen Y; Yang L
    Cancer Biol Ther; 2019; 20(6):837-842. PubMed ID: 30744539
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.